Aptevo Therapeutics Inc. — Director's Dealing 2019

Aug 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2019-08-12

Reporting Person: El-Hibri Fuad (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-12	Common Stock	P	100000	$0.7552	Acquired	1124536	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2172125	Indirect
Common Stock	762077	Indirect

Footnotes

F1: The transaction reported on this Form 4 was made by the Reporting Person pursuant to a trading plan adopted on May 31, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.4999 to $0.8000 per share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.

F3: The Reporting Person's wife, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., a Maryland limited liability company, which in turn beneficially owns an aggregate of 2,172,125 shares of common stock. The Reporting Person expressly disclaims beneficial ownership of any shares of common stock owned by Intervac, L.L.C., except to the extent of his pecuniary interest therein.

F4: The Reporting Person holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 762,077 shares of common stock. The Reporting Person disclaims beneficial ownership of the shares of common stock directly owned by Biovac, L.L.C., except to the extent of his pecuniary interest therein.